-
1 month ago | 
jwatch.org | Michael Billington
-
1 month ago | 
jwatch.org | Paul Mueller
Paul S. Mueller, MD, MPH, FACP, reviewing For patients with obesity, outcomes were similar regardless of whether they lost weight before surgery or not. Obesity (body-mass index [BMI], ≥30 kg/m 2) is associated with excess risk for complications after total hip arthroplasty (THA). As a result, many orthopedic surgeons recommend preoperative weight loss in patients with substantial obesity.
-
2 months ago | 
jwatch.org | Michael Billington
-
Mar 25, 2025 | 
jwatch.org | Paul Mueller
-
Jan 30, 2025 | 
jwatch.org | Peter Roy-Byrne
-
Jan 29, 2025 | 
jwatch.org | Behnood Bikdeli
Behnood Bikdeli, MD, MS, reviewing Findings from an industry-sponsored, phase 2 trial of abelacimab suggest reduced bleeding compared with rivaroxaban. Although direct oral anticoagulants (DOACs) are effective anticoagulants for patients with atrial fibrillation (AF), bleeding events can be catastrophic or impair patient adherence.
-
Jan 23, 2025 | 
jwatch.org | Shea E. Hogan
Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM, reviewing An exploratory analysis of randomized data demonstrates higher mortality and less clear benefit of mAFP use in older patients with STEMI-related cardiogenic shock. The DanGer Shock trial established that microaxial flow pump (mAFP) use decreases all-cause mortality in certain patients presenting with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock (CS; NEJM JW Cardiol Apr 8 2024 and N Engl J Med 2024; 390:1382).
-
Jan 21, 2025 | 
jwatch.org | Howard C Herrmann
Howard C. Herrmann, MD, reviewing The coronary sinus reducer, approved in Europe, appears to improve angina and quality of life in patients with CMD or refractory angina. Coronary microvascular dysfunction (CMD), characterized by abnormal vasodilatory capacity or intense vasoconstriction affecting smaller coronary arteries, can occur without epicardial obstructive coronary artery disease (CAD) and is a challenging condition without widely effective treatments.
-
Jan 21, 2025 | 
jwatch.org | Anthony Kim
Anthony S. Kim, MD, reviewing In a pooled individual patient-level meta-analysis of data from four trials, functional outcomes and mortality improved with endovascular therapy despite increased hemorrhage risks. Stroke thrombectomy trials have focused on mainly anterior-circulation large-vessel occlusion stroke.
-
Jan 16, 2025 | 
jwatch.org | Daniel D. Dressler
Daniel D. Dressler, MD, MSc, MHM, FACP, reviewing In patients with hip fracture and an elevated troponin level, rapid surgical intervention was associated with lower mortality. In the HIP ATTACK trial ( NEJM JW Gen Med Mar 15 2020 and Lancet 2020; 395:698), nearly 3000 patients who presented with hip fracture after low-energy trauma (e.g., ground-level fall) were randomized to undergo either accelerated surgery (i.e., within 6 hours) or standard-timing surgery (i.e., within 24 hours).